SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%
新闻
CCXI
--
0.00%
--
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 2天前
Stocks That Hit 52-Week Highs On Thursday
During Thursday's morning trading, 73 companies set new 52-week highs.
Benzinga · 3天前
Benzinga's Top Upgrades, Downgrades For May 27, 2020
Upgrades
Benzinga · 4天前
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 4天前
Wells Fargo Initiates Coverage On ChemoCentryx with Overweight Rating, Announces Price Target of $79
Wells Fargo analyst Yanan Zhu initiates coverage on ChemoCentryx (NASDAQ:CCXI) with a Overweight rating and announces Price Target of $79.
Benzinga · 4天前
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 118 companies set new 52-week highs.
Benzinga · 5天前
Profiting From The Consensus Stock Holdings Of Five Hedge Funds
Seeking Alpha - Article · 05/24 16:29
Stocks That Hit 52-Week Highs On Friday
On Friday, 46 stocks hit new 52-week highs.
Benzinga · 05/22 14:31
Stocks That Hit 52-Week Highs On Thursday
Thursday's morning session saw 48 companies set new 52-week highs.
Benzinga · 05/21 14:25
Canaccord Genuity Maintains Buy on ChemoCentryx, Lowers Price Target to $58
Canaccord Genuity maintains ChemoCentryx (NASDAQ:CCXI) with a Buy and lowers the price target from $68 to $58.
Benzinga · 05/19 15:35
Deciphera's GIST Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 05/19 08:21
ChemoCentryx's CCX140 comes up short in rare kidney disorder study
ChemoCentryx (NASDAQ:CCXI) and collaboration partner Vifor Fresenius Medical Care Renal Pharma announce "disappointing" topline data from a Phase 2 clinica
seekingalpha · 05/18 18:23
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire · 05/18 13:30
Analysts Have Just Cut Their ChemoCentryx, Inc. (NASDAQ:CCXI) Revenue Estimates By 11%
Simply Wall St. · 05/16 15:49
JP Morgan Maintains Overweight on ChemoCentryx, Raises Price Target to $64
JP Morgan maintains ChemoCentryx (NASDAQ:CCXI) with a Overweight and raises the price target from $61 to $64.
Benzinga · 05/14 13:19
ChemoCentryx, Inc. (NASDAQ:CCXI) Just Reported And Analysts Have Been Cutting Their Estimates
Simply Wall St. · 05/14 11:53
ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 19:35
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
ChemoCentryx Inc (CCXI) Q1 2020 Earnings Call Transcript
Motley Fool · 05/12 18:30
Canaccord Genuity Maintains Buy on ChemoCentryx, Raises Price Target to $68
Canaccord Genuity maintains ChemoCentryx (NASDAQ:CCXI) with a Buy and raises the price target from $64 to $68.
Benzinga · 05/12 16:20